GPBAR1 and metabolic dysfunction-associated steatotic liver disease: To validate the relevance of the CysLT1R/GPBAR1 in this model, we have first investigated whether the cystenyl-leukotriene pathway (Figure 4A) and that of GPBAR1 are modulated in the liver of NAFLD/NASH patients.